Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Valentina Barbui"'
Autor:
Katia Todoerti, Valentina Barbui, Olga Pedrini, Marta Lionetti, Gianluca Fossati, Paolo Mascagni, Alessandro Rambaldi, Antonino Neri, Martino Introna, Luigia Lombardi, Josée Golay
Publikováno v:
Haematologica, Vol 95, Iss 2 (2010)
Background The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease.Design and Methods In order to gain an overall view of the activity of ITF2357 and identi
Externí odkaz:
https://doaj.org/article/a1f3057522f148d6afed1d17f7626150
Autor:
Valentina Barbui, Olga Pedrini, Luigia Lombardi, Paolo Mascagni, Martino Introna, Katia Todoerti, Alessandro Rambaldi, Marta Lionetti, Gianluca Fossati, Josée Golay, Antonino Neri
Publikováno v:
Haematologica. 95:260-269
Background The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease.Design and Methods In order to gain an overall view of the activity of ITF2357 and identi
Autor:
Orietta Spinelli, Alessandro Rambaldi, Valentina Barbui, Anna Salvi, Alessandra Carobbio, Vittoria Guerini, T Barbui, Martino Introna, Josée Golay, Chiara Dellacasa
Publikováno v:
Leukemia. 22:740-747
We investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2(V617F) mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the
Autor:
Piero Bellavita, Agnese Salvadè, Benedetta Cabiati, Olga Pedrini, Valentina Barbui, Paolo Perseghin, Josée Golay, Ettore Biagi, Andrea Biondi, Daniela Belotti, Chiara Capelli, Elisa Gotti, Gianmaria Borleri, Martino Introna, Alessandro Rambaldi
BACKGROUND AIMS: Human multipotent mesenchymal stromal cells (hMSC) are considered good candidates for a growing spectrum of cell therapies. We have validated a protocol that makes use of the washouts of discarded collection sets, left over at the en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ca01925e857f7110f67295836fb7d2d
http://hdl.handle.net/10281/14925
http://hdl.handle.net/10281/14925
Autor:
Gianluca Fossati, Caterina Micò, G Porro, M Domenghini, Luigia Lombardi, P Pagani, Anna Salvi, P Pozzi, Paolo Mascagni, Martino Introna, Franco Leoni, Anna Maria Barbui, Lucia Cuppini, Antonino Neri, Valentina Barbui, Alessandro Rambaldi, Josée Golay
Publikováno v:
Leukemia. 21(9)
We have investigated the activity of ITF2357, a novel hydroxamate histone deacetylase inhibitor, on multiple myeloma (MM) and acute myelogenous leukemia (AML) cells in vitro and in vivo. ITF2357 induced apoptosis in 8/9 MM and 6/7 AML cell lines, as
Autor:
Tiziano Barbui, Martino Introna, Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Alessandro Rambaldi, Anna Salvi, Josée Golay, Chiara Dellacasa
Publikováno v:
Blood. 110:555-555
A somatic point mutation in the JAK2 gene (JAK2V617F) is the key pathogenetic lesion of Polycythemia Vera (PV) and Essential Thrombocythemia (ET) and a significant effort is now paid to identify drugs which may be able to interfere with the JAK2V617F